0001209191-23-037530.txt : 20230615 0001209191-23-037530.hdr.sgml : 20230615 20230615182329 ACCESSION NUMBER: 0001209191-23-037530 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230613 FILED AS OF DATE: 20230615 DATE AS OF CHANGE: 20230615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harrison Seth Loring CENTRAL INDEX KEY: 0001404955 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38938 FILM NUMBER: 231018860 MAIL ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Stoke Therapeutics, Inc. CENTRAL INDEX KEY: 0001623526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471144582 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-430-8200 MAIL ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141028 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-13 0 0001623526 Stoke Therapeutics, Inc. STOK 0001404955 Harrison Seth Loring C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD MA 01730 1 0 0 0 0 Director Stock Option (Right to Buy) 12.46 2023-06-13 4 A 0 19441 0.00 A 2033-06-12 Common Stock 19441 19441 D The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. /s/ Stephen Tulipano, Attorney-in-Fact 2023-06-15